BACKGROUND: Workplace surveillance identifies chronic beryllium disease (CBD) but it remains unknown over what time frame mild CBD will progress to a more severe form. METHODS: We examined physiology and treatment in 229 beryllium sensitization (BeS) and 171 CBD surveillance-identified cases diagnosed from 1982 to 2002. Never smoking CBD cases (81) were compared to never smoking BeS patients (83) to assess disease progression. We compared CBD machinists to non-machinists to examine effects of exposure. RESULTS: At baseline, CBD and BeS cases did not differ significantly in exposure time or physiology. CBD patients were more likely to have machined beryllium. Of CBD cases, 19.3% went on to require oral immunosuppressive therapy. At 30 years from first exposure, measures of gas exchange were significantly worse and total lung capacity was lower for CBD subjects. Machinists had faster disease progression as measured by pulmonary function testing and gas exchange. CONCLUSIONS: Medical surveillance for CBD identifies individuals at significant risk of disease progression and impairment with sufficient time since first exposure. Copyright 2009 Wiley-Liss, Inc.
BACKGROUND: Workplace surveillance identifies chronic beryllium disease (CBD) but it remains unknown over what time frame mild CBD will progress to a more severe form. METHODS: We examined physiology and treatment in 229 beryllium sensitization (BeS) and 171 CBD surveillance-identified cases diagnosed from 1982 to 2002. Never smoking CBD cases (81) were compared to never smoking BeSpatients (83) to assess disease progression. We compared CBD machinists to non-machinists to examine effects of exposure. RESULTS: At baseline, CBD and BeS cases did not differ significantly in exposure time or physiology. CBDpatients were more likely to have machined beryllium. Of CBD cases, 19.3% went on to require oral immunosuppressive therapy. At 30 years from first exposure, measures of gas exchange were significantly worse and total lung capacity was lower for CBD subjects. Machinists had faster disease progression as measured by pulmonary function testing and gas exchange. CONCLUSIONS: Medical surveillance for CBD identifies individuals at significant risk of disease progression and impairment with sufficient time since first exposure. Copyright 2009 Wiley-Liss, Inc.
Authors: P K Henneberger; D Cumro; D D Deubner; M S Kent; M McCawley; K Kreiss Journal: Int Arch Occup Environ Health Date: 2001-04 Impact factor: 3.015
Authors: Laura Welch; Knut Ringen; Eula Bingham; John Dement; Tim Takaro; William McGowan; Anna Chen; Patricia Quinn Journal: Am J Ind Med Date: 2004-09 Impact factor: 2.214
Authors: Douglas G Mack; Allison M Lanham; Michael T Falta; Brent E Palmer; Lisa A Maier; Andrew P Fontenot Journal: Am J Respir Crit Care Med Date: 2010-03-18 Impact factor: 21.405
Authors: Lisa A Maier; Briana Q Barkes; Margaret Mroz; Milton D Rossman; Juliana Barnard; May Gillespie; Allison Martin; Douglas G Mack; Lori Silveira; Richard T Sawyer; Lee S Newman; Andrew P Fontenot Journal: Respir Med Date: 2012-09-11 Impact factor: 3.415
Authors: Mike V Van Dyke; John W Martyny; Margaret M Mroz; Lori J Silveira; Matt Strand; Tasha E Fingerlin; Hiroe Sato; Lee S Newman; Lisa A Maier Journal: Am J Respir Crit Care Med Date: 2011-03-11 Impact factor: 21.405
Authors: James Crooks; Margaret M Mroz; Michael VanDyke; Alison McGrath; Christine Schuler; Erin C McCanlies; M Abbas Virji; Kenneth D Rosenman; Milton Rossman; Carol Rice; Dimitri Monos; Tasha E Fingerlin; Lisa A Maier Journal: Occup Environ Med Date: 2021-09-17 Impact factor: 4.402
Authors: Margaret M Mroz; John H Ferguson; Anna V Faino; Annyce Mayer; Matthew Strand; Lisa A Maier Journal: Respir Med Date: 2018-02-05 Impact factor: 3.415
Authors: Lori J Silveira; Matthew Strand; Michael V Van Dyke; Margaret M Mroz; Anna V Faino; Dana M Dabelea; Lisa A Maier; Tasha E Fingerlin Journal: PLoS One Date: 2017-11-16 Impact factor: 3.240